BACKGROUND Both ischemic and hemorrhagic events after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) contribute to risk of subsequent death. Yet, the impact of the timing of these events on subsequent mortality is less well understood.
CONCLUSIONS In an all-comers patient population treated with DES, MI, ST and MB within 2 years are not uncommon (w1 in 8 patients). Early ST and early MI increased substantially the risk of death, while MB had a less pronounced effect, emphasizing the importance of improved devices, drugs and technique to prevent their occurrence. METHODS We analyzed data of unselected patients who received Nobori Ò Biolimus A9 eluting stent within the large, prospective, single-arm, multicentre e-NOBORI registry. The primary endpoint was target lesion failure (TLF) defined as composite of cardiac death, target vessel related myocardial infarction (MI) and clinically driven target lesion revascularization at 1-year. An independent clinical events committee adjudicated all endpoint related adverse events.
RESULTS A total of 11919 patients were included in the analysis, of which 44.1%, 38.2%, 13.1% and 4.6% had stent lesion 20mm, 20-40mm, 40-60mm and >60mm, respectively. The mean age did not differ across four subgroups. There were more male patients with increased lesion length across groups (Table) . The proportion of diabetic patients (33.2 %, 31.4%, 32.5%, 36.8%, P¼0.036), hypertensive patients (71.0%, 70.5%, 73.3%, and 75.7, p¼0.021) and current smokers (26.7%, 27.6%, 26.4% and 21.6%, P¼0.038) were also different across subgroups. Other basic characteristics such as previous MI and pervious stroke did not differ (p!0.21). LAD was the most frequent (45.2%) target vessel in stent lesion 20 mm group, while RCA was the most frequent (41.1%) target vessel in stent lesion > 60mm group. Complex lesion type (B2þC) were 45.4%, 59.6%, 62.6% and 65.7% across the groups. Total number of lesions treated per patient were 1.7AE1.6, 2.0AE1.3, 2.6AE1.4 and 3.5AE1.9 respectively (P<0.01). Number of stents per lesion were 1.1AE0.3, 1.2AE0.4, 1.3AE0.5 and 1.5AE0.8 (p<0.01) respectively. There were no differences in diameter stenosis at baseline (on average 84.8%, p¼0.60) while after procedure they were 2.8%, 2.9%, 1.9% and 2.6% (P<0.01) respectively. At 1 year, there was no difference (P>0.35) in the rate of any death, cardiac death, and MI (Table) . Composite endpoints TLF was slightly higher in long lesion subgroups (2.9%, 3.4%, 4.7% and 4.2% respectively, p¼0.005). The rate of stent thrombosis was low and comparable across 4 subgroups (0.38%, 0.55%, 0.77% and 0.18%, p¼0.16).
CONCLUSIONS In a real-life practice registry, patients with long lesions showed favorable and similar clinical outcomes when treated with Nobori Biolimus A9 eluting stent. Although we cannot completely exclude the possibility of underreporting of events, especially of periprocedural MIs, the comparable and very low rate of stent thrombosis across different lesion length groups up to 1 year is encouraging. BACKGROUND We investigated whether non-invasive discrimination of chronic total occlusion (CTO), a complete interruption of coronary artery flow, and subtotal occlusion (STO), a functional total occlusion, is feasible using coronary computed tomography angiography (CTA). CTO and STO may be different in pathophysiology and clinical treatment strategy.
METHODS We included 486 consecutive patients (median age 63 years, male gender 82%) who showed a total of 553 completely occluded coronary arteries in coronary CTA. The length of occlusion, side branches, the shape of proximal stump, and collateral vessels were measured as anatomical findings. Transluminal attenuation gradient (TAG), which reflects intraluminal contrast kinetics and functional extent of collateral flow, was measured as a physiological surrogate. All patients were followed by invasive coronary angiography (CAG). 
RESULTS

